Chris H P van den Akker1, Johannes B van Goudoever1,2, Hania Szajewska3, Nicholas D Embleton4, Iva Hojsak5, Daan Reid6, Raanan Shamir7. 1. Department of Paediatrics, Emma Children's Hospital-AMC. 2. Department of Paediatrics, VU University Medical Center, Amsterdam, The Netherlands. 3. Department of Paediatrics, The Medical University of Warsaw, Warsaw, Poland. 4. Newcastle Neonatal Service, Newcastle Hospitals NHS Trust and Newcastle University, Newcastle upon Tyne, UK. 5. Children's Hospital Zagreb, University of Zagreb School of Medicine, Zagreb, Croatia. 6. Department of Epidemiology, University Medical Center Groningen, Groningen, The Netherlands. 7. Institute for Gastroenterology, Nutrition and Liver Diseases, Schneider Children's Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Abstract
OBJECTIVES: Several randomized controlled trials (RCTs) on the use of probiotics to reduce morbidity and mortality in preterm infants have provided inconsistent results. Although meta-analyses that group all of the used strains together are suggesting efficacy, it is not possible to determine the most effective strain that is more relevant to the clinician. We therefore used a network meta-analysis (NMA) approach to identify strains with greatest efficacy. METHODS: A PubMed search identified placebo-controlled or head-to-head RCTs investigating probiotics in preterm infants. From trials that recorded mortality, necrotizing enterocolitis, late-onset sepsis, or time until full enteral feeding as outcomes, data were extracted and Bayesian hierarchical random-effects models were run to construct a NMA. RESULTS: Fifty-one RCTs involving 11,231 preterm infants were included. Most strains or combinations of strains were only studied in one or a few RCTs. Only 3 of 25 studied probiotic treatment combinations showed significant reduction in mortality rates. Seven treatments reduced necrotizing enterocolitis incidence, 2 reduced late-onset sepsis, and 3 reduced time until full enteral feeding. There was no clear overlap of strains, which were effective on multiple outcome domains. CONCLUSIONS: This NMA showed efficacy in reducing mortality and morbidity only in a minority of the studied strains or combinations. This may be due to an inadequate number, or size, of RCTs, or due to a true lack of effect for certain species. Further large and adequately powered RCTs using strains with the greatest apparent efficacy will be needed to more precisely define optimal treatment strategies.
OBJECTIVES: Several randomized controlled trials (RCTs) on the use of probiotics to reduce morbidity and mortality in preterm infants have provided inconsistent results. Although meta-analyses that group all of the used strains together are suggesting efficacy, it is not possible to determine the most effective strain that is more relevant to the clinician. We therefore used a network meta-analysis (NMA) approach to identify strains with greatest efficacy. METHODS: A PubMed search identified placebo-controlled or head-to-head RCTs investigating probiotics in preterm infants. From trials that recorded mortality, necrotizing enterocolitis, late-onset sepsis, or time until full enteral feeding as outcomes, data were extracted and Bayesian hierarchical random-effects models were run to construct a NMA. RESULTS: Fifty-one RCTs involving 11,231 preterm infants were included. Most strains or combinations of strains were only studied in one or a few RCTs. Only 3 of 25 studied probiotic treatment combinations showed significant reduction in mortality rates. Seven treatments reduced necrotizing enterocolitis incidence, 2 reduced late-onset sepsis, and 3 reduced time until full enteral feeding. There was no clear overlap of strains, which were effective on multiple outcome domains. CONCLUSIONS: This NMA showed efficacy in reducing mortality and morbidity only in a minority of the studied strains or combinations. This may be due to an inadequate number, or size, of RCTs, or due to a true lack of effect for certain species. Further large and adequately powered RCTs using strains with the greatest apparent efficacy will be needed to more precisely define optimal treatment strategies.
Authors: Rebecca L Morgan; Geoffrey A Preidis; Purna C Kashyap; Adam V Weizman; Behnam Sadeghirad Journal: Gastroenterology Date: 2020-06-24 Impact factor: 22.682
Authors: Jeffrey R Singer; Emily G Blosser; Carlene L Zindl; Daniel J Silberger; Sean Conlan; Vincent A Laufer; Daniel DiToro; Clay Deming; Ranjit Kumar; Casey D Morrow; Julia A Segre; Michael J Gray; David A Randolph; Casey T Weaver Journal: Nat Med Date: 2019-11-07 Impact factor: 53.440
Authors: Ilse H de Lange; Charlotte van Gorp; Laurens D Eeftinck Schattenkerk; Wim G van Gemert; Joep P M Derikx; Tim G A M Wolfs Journal: Nutrients Date: 2021-05-19 Impact factor: 5.717
Authors: Mary Ellen Sanders; Daniel J Merenstein; Gregor Reid; Glenn R Gibson; Robert A Rastall Journal: Nat Rev Gastroenterol Hepatol Date: 2019-07-11 Impact factor: 46.802
Authors: Paul Fleming; Mark Wilks; Simon Eaton; Nicola Panton; Richard Hutchinson; Abena Akyempon; Pollyanna Hardy; Michael R Millar; Kate Costeloe Journal: Pediatr Res Date: 2020-09-18 Impact factor: 3.756
Authors: Johanne E Spreckels; Erik Wejryd; Giovanna Marchini; Baldvin Jonsson; Dylan H de Vries; Maria C Jenmalm; Eva Landberg; Eva Sverremark-Ekström; Magalí Martí; Thomas Abrahamsson Journal: Microorganisms Date: 2021-04-24